Compounds > podophyllotoxin
Page last updated: 2024-08-21

podophyllotoxin and Kahler Disease

podophyllotoxin has been researched along with Kahler Disease in 25 studies

Research

Studies (25)

TimeframeStudies, this research(%)All Research%
pre-19907 (28.00)18.7374
1990's3 (12.00)18.2507
2000's10 (40.00)29.6817
2010's4 (16.00)24.3611
2020's1 (4.00)2.80

Authors

AuthorsStudies
Bringmann, G; Brun, R; Brünnert, D; Chatterjee, M; Efferth, T; Feineis, D; Kaiser, M; Li, J; Mudogo, V; Seo, EJ; Seupel, R1
Bazarbachi, A; Bou Akl, I; El-Cheikh, J; Ghaoui, N; Karout, L; Khalil, PB; Massoud, R; Matar, M; Zahreddine, A1
Axelson, M; Bieghs, L; De Bruyne, E; Fostier, K; Jernberg-Wiklund, H; Johnsen, HE; Larsson, O; Lub, S; Maes, K; Menu, E; Nyegaard, M; Overgaard, MT; Schots, R; Van Valckenborgh, E; Vanderkerken, K1
Abboud, CN; Cashen, AF; DiPersio, JF; Fiala, MA; Fletcher, T; Stockerl-Goldstein, KE; Uy, GL; Vij, R; Wang, TF; Westervelt, P; Wu, N1
Agarwal, P; Atadja, P; Axelson, M; De Bruyne, E; Fristedt, C; Jernberg-Wiklund, H; Larsson, O; Lemaire, M; Menu, E; Österborg, A; Van Camp, B; Van Valckenborgh, E; Vanderkerken, K1
García, J; Lahuerta, JJ; Lizasoain, M; Sanz, F1
Asosingh, K; Axelson, M; De Raeve, H; Girnita, L; Jernberg-Wiklund, H; Larsson, O; Menu, E; Nilsson, K; Stromberg, T; Van Camp, B; Vanderkerken, K1
Albarello, A; Ballerini, F; Balocco, M; Canepa, L; Canepa, P; Clavio, M; Garrone, A; Gobbi, M; Michelis, GL; Miglino, M; Pierri, I; Varaldo, R1
Axelson, M; Carlson, K; Dimberg, LY; Ekman, S; Girnita, L; Hellman, U; Jernberg-Wiklund, H; Larsson, O; Lennartsson, J; Nilsson, K; Osterborg, A; Strömberg, T; Vanderkerken, K1
Bakshi, A; Bhagwat, R; Biswas, G; Khadwal, A; Narayanan, P; Parikh, P; Sastry, P1
Bauchmüller, K; Engelhardt, M; Finke, J; Haas, PS; Ihorst, G; Kühnemund, A1
Jernberg-Wiklund, H; Nilsson, K1
Axelson, M; Coulton, L; Croucher, P; De Leenheer, E; De Raeve, H; Gallagher, O; Jernberg-Wiklund, H; Larsson, O; Menu, E; Nilsson, K; Van Camp, B; Van Valckenborgh, E; Vanderkerken, K1
Carbone, A; Franchin, G; Galligioni, E; Grigoletto, E; Tirelli, U; Trovo, MG; Tumolo, S; Veronesi, A; Volpe, R1
Togawa, A1
Chen, PM; Chiou, TJ; Fang, FS; Hsieh, RK; Liu, JH; Tung, SL; Tzeng, CH; Wang, WS; Yen, CC1
Clark, RE; Durham, BH; Flory, AJ; Fraser, WD; Ion, EM; Woodcock, BE1
Inwards, DJ; Lacy, MQ; Markovic, SN; Porrata, LF1
Bonera, E; Calvi, A; Lombardi, C; Savio, A; Savio, E1
Dorr, RT; Gerner, EW; Liddil, JD1
Atzpodien, J; Clarkson, BD; Colvin, OM; Fried, J; Gulati, SC; Shimazaki, C1
Adler, G; Görg, C; Görg, K; Havemann, K; Pflüger, KH1
Bartolucci, AA; Gockerman, JP; Nelson, MO; Silberman, H; Stein, R; Velez-Garcia, E1
Brema, F; Carbone, A; Grigoletto, E; Tirelli, U; Veronesi, A; Volpe, R; Zagonei, V1
Bogdanikowa, B; Drozd, J; Obrzut, D; Palka, Z1

Reviews

1 review(s) available for podophyllotoxin and Kahler Disease

ArticleYear
Control of apoptosis in human multiple myeloma by insulin-like growth factor I (IGF-I).
    Advances in cancer research, 2007, Volume: 97

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dexamethasone; Drug Delivery Systems; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Humans; Insulin-Like Growth Factor I; Mice; Mice, Inbred BALB C; Mice, SCID; Models, Molecular; Multiple Myeloma; Neoplasm Proteins; Podophyllotoxin; Protein Conformation; Receptor, IGF Type 1; Ribosomal Protein S6 Kinases, 70-kDa; RNA, Small Interfering; Signal Transduction; Sirolimus

2007

Trials

6 trial(s) available for podophyllotoxin and Kahler Disease

ArticleYear
Impact of the Conditioning Regimen Dose Intensity Before Autologous Stem Cell Transplantation on the Pulmonary Function Test Abnormalities in Patients With Lymphoma and Multiple Myeloma: Single Center Experience.
    Clinical lymphoma, myeloma & leukemia, 2020, Volume: 20, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Cytarabine; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Lung; Lymphoma; Male; Melphalan; Middle Aged; Multiple Myeloma; Podophyllotoxin; Respiratory Function Tests; Retrospective Studies; Survival Rate; Transplantation Conditioning

2020
A phase II study of V-BEAM as conditioning regimen before second auto-SCT for multiple myeloma.
    Bone marrow transplantation, 2014, Volume: 49, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Boronic Acids; Bortezomib; Carmustine; Cytarabine; Female; Follow-Up Studies; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Podophyllotoxin; Pyrazines; Stem Cell Transplantation; Transplantation Conditioning

2014
Trial of amifostine in autologous stem cell transplant.
    Bone marrow transplantation, 2006, Volume: 37, Issue:1

    Topics: Adolescent; Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cytarabine; Female; Graft Survival; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Podophyllotoxin; Radiation-Protective Agents; Stem Cell Transplantation; Transplantation, Homologous

2006
Navoban (tropisetron, ICS 205-930) and dexamethasone combination in the prevention of vomiting for patients receiving preconditioning high-dose chemotherapy before marrow transplantation.
    Japanese journal of clinical oncology, 1998, Volume: 28, Issue:2

    Topics: Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Carmustine; Child; Cyclophosphamide; Cytarabine; Dexamethasone; Dizziness; Drug Therapy, Combination; Female; Headache; Heartburn; Humans; Indoles; Leukemia; Male; Melphalan; Middle Aged; Multiple Myeloma; Podophyllotoxin; Transplantation Conditioning; Tropisetron; Vomiting; Whole-Body Irradiation

1998
Phase II evaluation of etoposide in refractory multiple myeloma: a Southeastern Cancer Study Group Trial.
    Cancer treatment reports, 1986, Volume: 70, Issue:6

    Topics: Clinical Trials as Topic; Drug Evaluation; Etoposide; Female; Hematologic Diseases; Humans; Male; Middle Aged; Multiple Myeloma; Podophyllotoxin

1986
Phase II study of teniposide (VM-26) in multiple myeloma.
    American journal of clinical oncology, 1985, Volume: 8, Issue:4

    Topics: Adult; Aged; Blood Cell Count; Blood Proteins; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Immunoglobulins; Infusions, Parenteral; Leukopenia; Male; Middle Aged; Multiple Myeloma; Podophyllotoxin; Teniposide

1985

Other Studies

18 other study(ies) available for podophyllotoxin and Kahler Disease

ArticleYear
Dioncophyllines C
    Journal of natural products, 2017, 02-24, Volume: 80, Issue:2

    Topics: Alkaloids; Antimalarials; Antineoplastic Agents; Humans; Isoquinolines; Magnoliopsida; Molecular Structure; Multiple Myeloma; Nuclear Magnetic Resonance, Biomolecular; Plasmodium falciparum; Structure-Activity Relationship

2017
The IGF-1 receptor inhibitor picropodophyllin potentiates the anti-myeloma activity of a BH3-mimetic.
    Oncotarget, 2014, Nov-30, Volume: 5, Issue:22

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomimetic Materials; Biphenyl Compounds; Cell Line, Tumor; Drug Synergism; Humans; Mice; Mice, Inbred C57BL; Multiple Myeloma; Nitrophenols; Piperazines; Podophyllotoxin; Receptor, IGF Type 1; Sulfonamides

2014
The HDAC inhibitor LBH589 enhances the antimyeloma effects of the IGF-1RTK inhibitor picropodophyllin.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Apr-15, Volume: 18, Issue:8

    Topics: Animals; Apoptosis; Caspase 8; Cell Adhesion; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Drug Synergism; G2 Phase Cell Cycle Checkpoints; Gene Expression Profiling; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Mice; Mice, Inbred C57BL; Multiple Myeloma; Panobinostat; Podophyllotoxin; Receptor, IGF Type 1; Transcriptome; Tumor Cells, Cultured

2012
[Bacteremia due to Capnocytophaga spp.: two cases].
    Enfermedades infecciosas y microbiologia clinica, 2003, Volume: 21, Issue:3

    Topics: 4-Quinolones; Aged; Anti-Infective Agents; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Capnocytophaga; Carmustine; Combined Modality Therapy; Cytarabine; Drug Resistance, Multiple, Bacterial; Female; Gram-Negative Bacterial Infections; Hematopoietic Stem Cell Transplantation; Humans; Immunocompromised Host; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Multiple Myeloma; Podophyllotoxin; Transplantation Conditioning

2003
Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model.
    Blood, 2006, Jan-15, Volume: 107, Issue:2

    Topics: Animals; Bone Marrow; Cell Proliferation; Disease Models, Animal; Enzyme Activation; In Vitro Techniques; Insulin-Like Growth Factor I; Mice; Mice, Inbred C57BL; Microcirculation; Mitogen-Activated Protein Kinase 1; Multiple Myeloma; Neovascularization, Pathologic; Paraproteins; Phosphorylation; Podophyllotoxin; Receptor, IGF Type 1; Survival Rate; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A

2006
Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.
    Oncology reports, 2005, Volume: 14, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Epirubicin; Etoposide; Female; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Mitoxantrone; Multiple Myeloma; Odds Ratio; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Recurrence; Remission Induction; Salvage Therapy; Time Factors; Transplantation Conditioning; Treatment Outcome

2005
IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells.
    Blood, 2006, Jan-15, Volume: 107, Issue:2

    Topics: Apoptosis; CDC2 Protein Kinase; Cell Division; Cell Proliferation; Enzyme Activation; G2 Phase; Humans; Inhibitor of Apoptosis Proteins; Insulin; Insulin-Like Growth Factor I; Interleukin-6; Microtubule-Associated Proteins; Mitogen-Activated Protein Kinase 1; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Phosphorylation; Podophyllotoxin; Proto-Oncogene Proteins c-bcl-2; Receptor, IGF Type 1; Receptor, Insulin; Survivin; Tumor Cells, Cultured

2006
Efficacy of diverse high-dose regimens followed by autologous peripheral blood stem cell transplantation in consecutive multiple myeloma patients: a single-centre analysis over a 12-year period.
    Annals of hematology, 2006, Volume: 85, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Remission Induction; Retrospective Studies; Transplantation, Autologous

2006
Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: beneficial effects on tumor growth, angiogenesis, bone disease and survival.
    International journal of cancer, 2007, Oct-15, Volume: 121, Issue:8

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Bone Neoplasms; Disease Models, Animal; Kaplan-Meier Estimate; Mice; Multiple Myeloma; Neovascularization, Pathologic; Podophyllotoxin; Receptor, IGF Type 1

2007
VM26 in malignant hematological diseases. A phase II study.
    Cancer chemotherapy and pharmacology, 1982, Volume: 7, Issue:2-3

    Topics: Drug Evaluation; Hodgkin Disease; Humans; Leukemia, Lymphoid; Lymphoma; Multiple Myeloma; Podophyllotoxin; Teniposide

1982
[Recent therapy for refractory myeloma].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 1993, Volume: 34, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Administration Schedule; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Nitrosourea Compounds; Podophyllotoxin; Prednisone; Remission Induction; Survival Rate; Vincristine

1993
Biochemical markers of bone turnover following high-dose chemotherapy and autografting in multiple myeloma.
    Blood, 2000, Oct-15, Volume: 96, Issue:8

    Topics: Adult; Aged; Alkaline Phosphatase; Amino Acids; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Remodeling; Bone Resorption; Carmustine; Clodronic Acid; Combined Modality Therapy; Cytarabine; Disease Progression; Female; Hematopoietic Stem Cell Transplantation; Humans; Isoenzymes; Male; Melphalan; Middle Aged; Multiple Myeloma; Osteoclasts; Peptide Fragments; Podophyllotoxin; Procollagen; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome

2000
Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-alpha in autologous stem cell transplantation.
    Bone marrow transplantation, 2001, Volume: 28, Issue:7

    Topics: Adjuvants, Immunologic; Adult; Aged; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cells, Cultured; Cytarabine; Cytotoxicity Tests, Immunologic; Cytotoxicity, Immunologic; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunophenotyping; Interferon-alpha; Interleukin-2; K562 Cells; Killer Cells, Natural; Lymphocyte Count; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Multiple Myeloma; Podophyllotoxin; Time Factors; Transplantation Conditioning; Transplantation, Autologous

2001
Bilateral breast involvement in a 71-year-old white man with lambda light chain disease. Regression after a new chemotherapy combination. A case report.
    Tumori, 1992, Feb-29, Volume: 78, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dexamethasone; Humans; Immunoglobulin lambda-Chains; Male; Melphalan; Multiple Myeloma; Peptichemio; Podophyllotoxin; Prednisone; Remission Induction; Time Factors

1992
Modulation of etoposide cytotoxicity and DNA strand scission in L1210 and 8226 cells by polyamines.
    Cancer research, 1986, Volume: 46, Issue:8

    Topics: Animals; Cell Survival; DNA Topoisomerases, Type II; DNA, Neoplasm; DNA, Single-Stranded; Eflornithine; Etoposide; Humans; Leukemia L1210; Mice; Multiple Myeloma; Nucleic Acid Conformation; Ornithine; Podophyllotoxin; Polyamines; Putrescine

1986
Ex vivo treatment of myeloma cells by 4-hydroperoxycyclophosphamide and VP-16-213.
    Acta haematologica, 1988, Volume: 80, Issue:1

    Topics: Bone Marrow; Cell Communication; Cell Line; Cell Survival; Colony-Forming Units Assay; Cyclophosphamide; Hematopoiesis; Humans; Multiple Myeloma; Neoplastic Stem Cells; Podophyllotoxin

1988
Multiple myeloma of the serosa coat.
    Journal of cancer research and clinical oncology, 1988, Volume: 114, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans; Immunoglobulin A; Male; Melphalan; Microscopy, Electron; Multiple Myeloma; Podophyllotoxin; Prednisone; Serous Membrane; Vincristine

1988
[Effect of podophyllin alkaloids on the blood protein pattern in multiple myeloma].
    Polski tygodnik lekarski (Warsaw, Poland : 1960), 1970, Aug-10, Volume: 25, Issue:32

    Topics: Adult; Aged; Alkaloids; Blood Proteins; Female; Humans; Male; Middle Aged; Multiple Myeloma; Phytotherapy; Plants, Medicinal; Plants, Toxic; Podophyllum

1970